Characterization of the Antispike IgG Immune Response to COVID-19 Vaccines in People with a Wide Variety of Immunodeficiencies

In a prospective cohort of 195 immune-deficient/disordered people and 35 healthy volunteers, antispike immunoglobulin G (IgG) was detected in 88% ofi mmune-deficient/disordered people after dose two, increasing to 93% by six months after dose three.